Phase I/II study of DHA–paclitaxel in combination with carboplatin in patients with advanced malignant solid tumours

DHA–paclitaxel is a conjugate of paclitaxel and the fatty acid, docosahexaenoic acid. Preclinical studies have demonstrated increased activity, relative to paclitaxel, with the potential for an improved therapeutic ratio. We conducted a phase I study to determine the maximum tolerated doses of DHA–p...

Descripción completa

Detalles Bibliográficos
Autores principales: Harries, M, O'Donnell, A, Scurr, M, Reade, S, Cole, C, Judson, I, Greystoke, A, Twelves, C, Kaye, S
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2004
Materias:
Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2410023/
https://www.ncbi.nlm.nih.gov/pubmed/15494716
http://dx.doi.org/10.1038/sj.bjc.6602196

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2410023/
https://www.ncbi.nlm.nih.gov/pubmed/15494716
http://dx.doi.org/10.1038/sj.bjc.6602196

Ejemplares similares